Study S003307

A Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of LY3549492 Compared With Placebo in Adult Participants Aged 55 to 80 Years With a BMI of 22 to 25 kg/m2

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT07085468
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: TERMINATED
Enrollment: 1
Start: 2025-07-21
Primary completion: 2025-08-14
Lead sponsor: Eli Lilly and Company
Conditions: Healthy
Interventions: DRUG:LY3549492; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J3H-MC-GZNI

Registered primary outcomes

Number of Participants With One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 48]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.